Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-03-24
1999-12-14
Moezie, M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514282, 514284, 514651, 514811, A61K 3144
Patent
active
060018488
ABSTRACT:
Disclosed are dopamine agonist and opioidergic compositions and methods for their use in the treatment of alcoholism. The invention discloses compounds and therapeutic kits useful in the treatment of alcoholics having the A1 allele of the dopamine receptor D2 gene. Also disclosed are methods of treating alcoholics having the A1/A1 or A1/A2 DRD2 genotype comprising administration of dopamine agonists such as aporphines, ergolines, related compounds, and their analogs, in combination with opioidergic compounds such as naloxone.
REFERENCES:
patent: 4882335 (1989-11-01), Sinclair
patent: 5210016 (1993-05-01), Blum et al.
patent: 5298622 (1994-03-01), Portoghese et al.
patent: 5500343 (1996-03-01), Blum et al.
patent: 5550021 (1996-08-01), Blum et al.
O'Malley et al., "Naltrexone and Coping Skills Therapy for Alcohol Dependence," Arch. Gen. Psychiatry, 49:881-887, Nov. 1992.
McBride et al., "Serotonin, Dopamine and GABA Involvement in Alcohol Drinking of Selectively Bred Rats," Alcohol, 7:199-205, 1990.
Dyr et al., "Effects of D.sub.1 and D.sub.2 Dopamine Receptor Agents on Ethanol Consumption in the High-Alcohol-Drinking (HAD) Lines of Rats," Alcohol, 10:207-212, 1993.
Rassnick et al., "SDZ-205, 152, a Novel Dopamine Receptor Agonist, Reduces Oral Ethanol Self-Administration in Rats," Alcohol, 10:127-132, 1993.
Uhl et al., "Substance Abuse Vulnerability and D.sub.2 Receptor Gene," Trends Neurosci., 16:83-88, 1993.
Weiss et al., "Free-Choice Responding for Ethanol Versus Water in Alcohol Preferring (P) and Unselected Wistar Rats is Differentially Modified by Naloxone, Bromocriptine and Methysergide," Psychopharmacology, 101:178-186, 1990.
Noble, "The D.sub.2 Dopamine Receptor Gene: A Review of Association Studies in Alcoholism," Behav. Genet., 23:119-129, 1993.
Noble and Blum, "Alcoholism and the D.sub.2 Receptor Gene (Letter)," J. Am. Med. Assoc., 270;1547, Oct. 1993.
Noble et al., "Allelic Association of the D.sub.2 Dopamine Receptor Gene with Receptor-Binding Characteristics in Alcoholism," Arch. Gen. Psychiatr., 48:648-654, Jul. 1991.
Noble et al., "Allelic Association of the D.sub.2 Dopamine Receptor Gene with cocaine Dependence," Drug. Alc. Depend., 33:271-285, 1993.
Noble et al. "Prolonged P300 latency in children with the D.sub.2 dopamine receptor A1 allele," Am. J. Hum. Genet., 54:658-668, 1994.
Noble et al., "D.sub.2 dopamine receptor gene and obesity," Int. Eating Disord., 15:205-217, 1994.
Noble et al., "D.sub.2 Dopamine Receptor Gene and Cigarette Smoking: A Reward Gene?" Med. Hypotheses, 42:257-260, 1994.
Berman and Noble, "Reduced Visuospatial Performance in Children with the D.sub.2 Dopamine Receptor A1 Allele," Behav. Genet., 25:45-48, 1995.
Benjamin et al., "Naltrexone Reverses Ethanol-Induced Dopamine Release in the Nucleus Accumbens in Awake, Freely Moving Rats," Brain Res., 621:137-140, 1993.
Bohn et al., "Naltrexone and Brief Counseling to Reduce Heavy Drinking," Am. J. Addictions, 3:91-99, 1994.
Borg, "Bromocriptine in the prevention of alcohol abuse," Acta Psychiat. Scand., 68:100-111, 1983.
Borg and Weinholdt, "A Preliminary Study of Two Dopaminergic Drugs, Apomorphine and Bromocriptine (Parlodel), in the Treatment of the Alcohol-Withdrawal Syndrome," Curr. Ther. Res., 27:170-177, Feb. 1980.
Borg and Weinholdt, "Bromocriptine in the Treatment of the Alcohol-Withdrawal Syndrome," Acta Psychiat. Scand., 65:101-111, 1982.
Dongier et al., "Bromocriptine in the Treatment of Alcohol Dependence," Alcoholism, 15:970-977, Nov./Dec. 1991.
Powell et al., "A Double-Blind, Placebo-Controlled Study of Nortriptyline and Bromocriptine in Male Alcoholic Subtyped by Comorbid Psychiatric Disorders," Alcoholism, 19:463-468, Apr. 1995.
Liskow and Goodwin, "Pharmacological Treatment of Alcohol Intoxication, Withdrawal and Dependence: A Critical Review," J. Stud. Alcohol, 48:356-370, 1987.
Litten and Allen, "Pharmacotherapies for Alcoholism: Promising Agents and Clinical Issues," Alcoholism, 15:620-633, Jul./Aug. 1991.
Gorelick, "Medications for the Treatment of Substance Abuse," Curr. Opin. Psychiatr., 5:430-435, 1992.
Lawford et al., "Bromocriptine in the treatment of alcoholics with the D.sub.2 dopamine receptor A1 allele," Nature Med., 1:337-341, Apr. 1995.
O'Brien, "Rat study sheds light on cocaine craving", Science, 271:1499, Mar. 1996.
Parkes, "Medical intelligence: drug therapy: bromocriptine", New Engl. J. Med., 301:873-878, 1979.
Muller and Cramon, "Dopaminergic stimulation of brain damaged patients with bromocriptine and pergolide: a pharmacological approach to treat attentional deficits and apathy?" Neuropschychopharmacology, 10:3S:175S, May, 1994, (P-117-88).
Dackis et al., "Single-dose bromocriptine reverses cocaine craving", Psych. Res., 20:261-264, 1987.
Tennant and Sagherian, "Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence", Arch. Intern. Med., 147:109-112, Jan. 1987.
Anton, "New directions in the pharmacotherapy of alcoholism", Psychiatric Annals, 25:6:353-362, Jun. 1995.
Giannini et al., "Bromocriptine and amantadine in cocaine detoxification", Psychiatry Res., 29:11-16, 1989.
Dackis et al., "Bromocriptine treatment for cocaine abuse: the dopamine hypothesis", Intl. J. Psychiatr. Med., 15(2):125-135, 185-86.
Hitzig, "Combined dopamine and serotonin agonists: A synergistic approach to alcoholism and other addictive behaviors", Maryland Medical Journal, 42:153-157, Feb. 1993.
Hubner and Koob, "Bromocriptine produces decreases in cocaine self-administration in the rat", Neuropsychopharmacology, 3:101-108, 1990.
Naeger and Martinez, "The effect of tetrahydropapaveroline, bromocriptine, haloperidol, and lithium on voluntary ethanol ingestion", Proc. West. Pharmacol. Soc., 33:205-208, 1990.
Goldman, "Bromocriptine in the treatment of alcoholics", (letter to editor) Nature Medicine, 1:720, Aug. 1995.
Noble et al., "Bromocriptine in the treatment of alcoholics", (reply to Golman letter) Nature Medicine, 1:720-1, Aug. 1995.
Ng and George, "Dopamine receptor agonist reduces ethanol self-administration in the ethanol-preferring C57BL/6J inbred mouse", European Journal of Pharmacology, 269:365-374, 1994.
Uzbay et al., "Effects of bromocriptine and haloperidol on ethanol withdrawal syndrome in rats", Pharmacology Biochemistry and behavior, 49:969-974, 1994.
Manopulo et al., "Management of alcohol withdrwal syndrome experience with bromocriptine", Clinica Terapeutica, 116:297-302, 1986.
Burroughs et al., "Double-blind controlled trial of bromocriptine, chlordiazepoxide and chlormethiazole for alcohol withdrawal symptoms", Alcohol & Alcoholism, 20:263-271, 1985.
Nuotto and Mattila, "Failure of amantadine and bromocriptine to counteract alcoholic inebriation in man", Acta pharmacol. et toxicol., 55:168-173, 1984.
Neiswanger et al., "What can the DRD2/alcoholism story teach us about association studies in psychiatric genetics?", American Journal of Medical Genetics (Neuropsychiatric Genetics), 60:272-275, 1995.
Neiswanger et al., "Association and linkage studies of the TAQI A1 allele at the dopamine D.sub.2 receptor gene in samples of female and male alcoholics", American Journal of Medical Genetics (Neuropsychiatric Genetics), 60:267-271, 1995.
Moezie M.
The Regents of the University of California
LandOfFree
Bromocriptine for the treatment of alcoholics diagnosed with the does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bromocriptine for the treatment of alcoholics diagnosed with the, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bromocriptine for the treatment of alcoholics diagnosed with the will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-863732